ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Meredith Cook Sells 500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction on Tuesday, October 13th. The stock was sold at an average price of $73.59, for a total value of $36,795.00. Following the transaction, the vice president directly owned 73,424 shares of the company’s stock, valued at approximately $5,403,272.16. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total value of $35,395.00.
• On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total value of $37,740.00.

ANI Pharmaceuticals Trading Down 1.0%

Shares of ANIP stock opened at $70.16 on Thursday. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 15.12, a PEG ratio of 2.28 and a beta of 0.50. The stock has a 50-day moving average of $73.92 and a 200-day moving average of $78.01. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 1-year low of $69.58 and a 1-year high of $97.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same period in the previous year, the firm earned $1.80 earnings per share. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ANIP. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Guggenheim lowered their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock. Oppenheimer initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price on the stock. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Hold” and an average price target of $99.60.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership increased its stake in shares of ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after acquiring an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after acquiring an additional 43,523 shares during the period. Ranger Investment Management L.P. bought a new position in ANI Pharmaceuticals during the second quarter worth $28,406,000. Deutsche Bank AG bought a new position in ANI Pharmaceuticals during the second quarter worth $26,775,000. Finally, William Blair Investment Management LLC bought a new position in ANI Pharmaceuticals during the second quarter worth $21,372,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.